The Vanguard Study: Testing a New Way to Screen for Cancer

June 10, 2026 updated by: National Cancer Institute (NCI)
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

PRIMARY OBJECTIVES:

I. Assess the feasibility of recruitment and adherence to protocol-required baseline and follow-up data and blood collection.

II. Assess the feasibility of achieving representative enrollment across participating recruitment sites.

SECONDARY OBJECTIVES:

I. To assess the impact of participant blinding on willingness to participate, adherence to protocol required baseline and follow-up data, blood collection, and rates of standard of care screening.

II. To determine the timeliness of returning test results to participants. III. To understand the factors contributing to lack of diagnostic resolution of an abnormal MCD test.

IV. To examine the effects of participant characteristics, including cancer risk factors and social determinants of health, on all aspects of feasibility.

V. To estimate the proportion of participants receiving an MCD test outside of the trial.

VI. To assess the feasibility of a staggered introduction of the second MCD assay intervention arm.

VII. To estimate the proportion of abnormal MCD tests that are diagnostically resolved, and the time to resolution.

VIII. To compare the proportion of participants who receive standard of care screening during follow-up between the intervention and control arms.

IX. To assess the accuracy of tissue of origin prediction for each MCD assay. X. To estimate the incidence of complications related to diagnostic evaluation of an abnormal MCD test result.

XI. To assess the effect of an abnormal MCD test and diagnostic workup on anxiety and cancer worry.

XII. To evaluate the clinical diagnostic performance of the MCD assays.

EXPLORATORY OBJECTIVES:

I. To estimate rates of late-stage cancer, and the distribution of cancer stage.

II. To estimate assay-targeted cancer-specific mortality of each MCD assay, all cancer-specific mortality, and all-cause mortality.

III. To develop preliminary estimates of the total and incremental budget impact of MCD testing compared to current screening practice from the payor perspective.

IV. To develop preliminary estimates of the economic burden and impact of MCD testing from the participant perspective.

V. To assess the willingness of participants who reported military service to describe military-related environmental exposures by completing the Military Exposure Questionnaire.

OUTLINE: Participants are randomized to 1 of 3 arms.

ARM I: Participants undergo blood collection for Shield MCD testing at enrollment and after one year on study. Participants at unblinded sites are provided results of tests and those with abnormal results follow up with their clinician for additional testing. Participants at blinded sites are provided abnormal results and will follow up with their clinician for additional testing.

ARM II: Participants undergo blood collection for Avantect MCD testing at enrollment and after one year on study. Participants at unblinded sites are provided results of tests and those with abnormal results follow up with their clinician for additional testing. Participants at blinded sites are provided abnormal results and will follow up with their clinician for additional testing.

ARM III (Control): Participants undergo blood collection at enrollment and after one year on study.

After completion of study intervention, participants are followed passively up to 10 years.

Study Type

Interventional

Enrollment (Estimated)

24000

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Pleasanton, California, United States, 94588
        • Recruiting
        • Kaiser Permanente-Division of Research
        • Contact:
          • Site Public Contact
          • Phone Number: 510-891-3400
        • Principal Investigator:
          • Jeffrey Lee
    • Colorado
      • Cheyenne Wells, Colorado, United States, 80810
        • Recruiting
        • Keefe Memorial Hospital
        • Contact:
        • Principal Investigator:
          • Linda S. Cook
      • Denver, Colorado, United States, 80205
        • Recruiting
        • Kaiser Permanente-Franklin
        • Principal Investigator:
          • Debra P. Ritzwoller
        • Contact:
      • Fort Collins, Colorado, United States, 80524
        • Recruiting
        • Poudre Valley Hospital
        • Contact:
          • Site Public Contact
          • Phone Number: 970-297-6150
        • Principal Investigator:
          • Linda S. Cook
      • Fort Collins, Colorado, United States, 80528
        • Recruiting
        • Cancer Care and Hematology-Fort Collins
        • Contact:
        • Principal Investigator:
          • Linda S. Cook
      • Greeley, Colorado, United States, 80631
        • Recruiting
        • UCHealth Greeley Hospital
        • Contact:
        • Principal Investigator:
          • Linda S. Cook
      • Lafayette, Colorado, United States, 80026
        • Recruiting
        • Kaiser Permanente-Rock Creek
        • Principal Investigator:
          • Debra P. Ritzwoller
        • Contact:
      • Lone Tree, Colorado, United States, 80124
        • Recruiting
        • Kaiser Permanente-Lone Tree
        • Principal Investigator:
          • Debra P. Ritzwoller
        • Contact:
      • Loveland, Colorado, United States, 80538
        • Recruiting
        • Medical Center of the Rockies
        • Contact:
          • Site Public Contact
          • Phone Number: 970-203-7083
        • Principal Investigator:
          • Linda S. Cook
    • Hawaii
      • Honolulu, Hawaii, United States, 96819
        • Recruiting
        • Kaiser Permanente Moanalua Medical Center
        • Contact:
        • Principal Investigator:
          • Stacey Honda
    • Michigan
      • Brownstown, Michigan, United States, 48183
        • Recruiting
        • Henry Ford Cancer Institute-Downriver
        • Contact:
        • Principal Investigator:
          • Christine Neslund-Dudas
      • Brownstown, Michigan, United States, 48183
        • Recruiting
        • Henry Ford Health Center - Brownstown
        • Principal Investigator:
          • Christine Neslund-Dudas
        • Contact:
      • Chesterfield, Michigan, United States, 48047
        • Recruiting
        • Henry Ford Health Center - Chesterfield
        • Principal Investigator:
          • Christine Neslund-Dudas
        • Contact:
      • Clinton Township, Michigan, United States, 48038
        • Recruiting
        • Henry Ford Macomb Hospital-Clinton Township
        • Contact:
        • Principal Investigator:
          • Christine Neslund-Dudas
      • Dearborn, Michigan, United States, 48126
        • Recruiting
        • Henry Ford Medical Center-Fairlane
        • Contact:
        • Principal Investigator:
          • Christine Neslund-Dudas
      • Detroit, Michigan, United States, 48202
        • Recruiting
        • Henry Ford Hospital
        • Contact:
        • Principal Investigator:
          • Christine Neslund-Dudas
      • Detroit, Michigan, United States, 48235
        • Recruiting
        • Henry Ford Medical Center - Detroit Northwest
        • Principal Investigator:
          • Christine Neslund-Dudas
        • Contact:
      • Grosse Pointe Farms, Michigan, United States, 48236
        • Recruiting
        • Henry Ford Medical Center-Cottage
        • Principal Investigator:
          • Christine Neslund-Dudas
        • Contact:
          • Site Public Contact
          • Phone Number: 313-916-1784
      • Livonia, Michigan, United States, 48150
        • Recruiting
        • Henry Ford Medical Center - Livonia
        • Principal Investigator:
          • Christine Neslund-Dudas
        • Contact:
      • Novi, Michigan, United States, 48377
        • Recruiting
        • Henry Ford Medical Center-Columbus
        • Contact:
        • Principal Investigator:
          • Christine Neslund-Dudas
      • Plymouth, Michigan, United States, 48170
        • Recruiting
        • Henry Ford Medical Center - Plymouth
        • Principal Investigator:
          • Christine Neslund-Dudas
        • Contact:
      • Royal Oak, Michigan, United States, 48067
        • Recruiting
        • Henry Ford Medical Center - Royal Oak
        • Principal Investigator:
          • Christine Neslund-Dudas
        • Contact:
      • Sterling Heights, Michigan, United States, 48310
        • Recruiting
        • Henry Ford Medical Center
        • Contact:
        • Principal Investigator:
          • Christine Neslund-Dudas
      • Troy, Michigan, United States, 48083
        • Recruiting
        • Henry Ford Medical Center - Troy
        • Principal Investigator:
          • Christine Neslund-Dudas
        • Contact:
      • West Bloomfield, Michigan, United States, 48322
        • Recruiting
        • Henry Ford West Bloomfield Hospital
        • Contact:
        • Principal Investigator:
          • Christine Neslund-Dudas
      • Wyandotte, Michigan, United States, 48192
        • Recruiting
        • Henry Ford Wyandotte Hospital
        • Contact:
        • Principal Investigator:
          • Christine Neslund-Dudas
    • Missouri
      • Kansas City, Missouri, United States, 64111
        • Recruiting
        • Saint Luke's Hospital of Kansas City
        • Contact:
        • Principal Investigator:
          • Timothy J. Pluard
      • St Louis, Missouri, United States, 63110
        • Recruiting
        • Washington University School of Medicine
        • Contact:
        • Principal Investigator:
          • Aimee S. James
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27599
        • Recruiting
        • UNC Lineberger Comprehensive Cancer Center
        • Contact:
        • Principal Investigator:
          • Daniel S. Reuland
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73104
        • Recruiting
        • University of Oklahoma Health Sciences Center
        • Contact:
        • Principal Investigator:
          • Mark Doescher
    • Virginia
      • Charlottesville, Virginia, United States, 22911
        • Recruiting
        • Sentara Martha Jefferson Hospital
        • Contact:
          • Site Public Contact
          • Phone Number: 434-654-8400
        • Principal Investigator:
          • John M. Sayles
      • Fairfax, Virginia, United States, 22031
        • Recruiting
        • Inova Schar Cancer Institute
        • Principal Investigator:
          • Rebecca D. Kaltman
        • Contact:
      • Fairfax, Virginia, United States, 22033
        • Recruiting
        • Inova Fair Oaks Hospital
        • Principal Investigator:
          • Rebecca D. Kaltman
        • Contact:
      • Norfolk, Virginia, United States, 23507
        • Recruiting
        • Sentara Norfolk General Hospital
        • Contact:
          • Site Public Contact
          • Phone Number: 757-388-2406
        • Principal Investigator:
          • John M. Sayles
      • Richmond, Virginia, United States, 23235
        • Recruiting
        • VCU Massey Cancer Center at Stony Point
        • Contact:
        • Principal Investigator:
          • Alexander H. Krist
      • Richmond, Virginia, United States, 23298
        • Recruiting
        • VCU Massey Comprehensive Cancer Center
        • Principal Investigator:
          • Alexander H. Krist
        • Contact:
      • South Hill, Virginia, United States, 23970
        • Recruiting
        • VCU Community Memorial Health Center
        • Contact:
        • Principal Investigator:
          • Alexander H. Krist

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Ages 45-75 years old
  • Agree to provide blood samples for possible MCD testing at enrollment and at 1 year following enrollment
  • Agree to allow collection of information from their medical records for study-related purposes

  • Understand and be able to complete informed consent and participant questionnaires in English, Spanish, or Arabic

    • Note: Eligibility for Spanish and Arabic languages are at the Hub's discretion

Exclusion Criteria:

  • Solid malignant tumor or blood cancer diagnosis, with or without treatment, within the last 5 years

    • Note: Persons with a history of in situ cancers (e.g., ductal carcinoma in situ of the breast, cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ) or nonmelanoma skin cancer are eligible
  • Ongoing cancer diagnostic work-up
  • Ongoing participation in another study of an investigational cancer screening test or technology
  • Currently breastfeeding or pregnant, or planning to become pregnant in the next year

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Arm III (Control)
Participants undergo blood collection at enrollment and after one year on study.
Procedure: Biospecimen Collection
Undergo blood collection
Other Names:
  • Biological Sample Collection
  • Biospecimen Collected
  • Specimen Collection
  • Sample Collection
Other: Electronic Health Record Review
Obtain health data
Other: Questionnaire Administration
Study specific questionnaires
Experimental: Arm I (Shield MCD test)
Participants undergo blood collection for Shield MCD testing at enrollment and after one year on study. Participants at unblinded sites are provided results of tests and those with abnormal results follow up with their clinician for additional testing. Participants at blinded sites are provided abnormal results and will follow up with their clinician for additional testing.
Procedure: Biospecimen Collection
Undergo blood collection
Other Names:
  • Biological Sample Collection
  • Biospecimen Collected
  • Specimen Collection
  • Sample Collection
Procedure: Multi-Cancer Detection Test
Undergo Shield MCD test
Other Names:
  • MCD Assay
  • MCD Test
  • MCED Assay
  • MCED Test
  • Multi Cancer Detection Assay
  • Multi Cancer Detection Test
  • Multi Cancer Early Detection Assay
  • Multi Cancer Early Detection Test
  • Multi-Cancer Detection Assay
  • Multi-Cancer Early Detection Assay
  • Multi-Cancer Early Detection Test
Procedure: Multi-Cancer Detection Test
Undergo Avantect MCD test
Other Names:
  • MCD Assay
  • MCD Test
  • MCED Assay
  • MCED Test
  • Multi Cancer Detection Assay
  • Multi Cancer Detection Test
  • Multi Cancer Early Detection Assay
  • Multi Cancer Early Detection Test
  • Multi-Cancer Detection Assay
  • Multi-Cancer Early Detection Assay
  • Multi-Cancer Early Detection Test
Device: Device Usage
Evaluation of MCD tests
Other Names:
  • Usage of Device
Other: Electronic Health Record Review
Obtain health data
Other: Questionnaire Administration
Study specific questionnaires
Experimental: Arm II (Avantect MCD test)
Participants undergo blood collection for Avantect MCD testing at enrollment and after one year on study. Participants at unblinded sites are provided results of tests and those with abnormal results follow up with their clinician for additional testing. Participants at blinded sites are provided abnormal results and will follow up with their clinician for additional testing.
Procedure: Biospecimen Collection
Undergo blood collection
Other Names:
  • Biological Sample Collection
  • Biospecimen Collected
  • Specimen Collection
  • Sample Collection
Procedure: Multi-Cancer Detection Test
Undergo Shield MCD test
Other Names:
  • MCD Assay
  • MCD Test
  • MCED Assay
  • MCED Test
  • Multi Cancer Detection Assay
  • Multi Cancer Detection Test
  • Multi Cancer Early Detection Assay
  • Multi Cancer Early Detection Test
  • Multi-Cancer Detection Assay
  • Multi-Cancer Early Detection Assay
  • Multi-Cancer Early Detection Test
Procedure: Multi-Cancer Detection Test
Undergo Avantect MCD test
Other Names:
  • MCD Assay
  • MCD Test
  • MCED Assay
  • MCED Test
  • Multi Cancer Detection Assay
  • Multi Cancer Detection Test
  • Multi Cancer Early Detection Assay
  • Multi Cancer Early Detection Test
  • Multi-Cancer Detection Assay
  • Multi-Cancer Early Detection Assay
  • Multi-Cancer Early Detection Test
Device: Device Usage
Evaluation of MCD tests
Other Names:
  • Usage of Device
Other: Electronic Health Record Review
Obtain health data
Other: Questionnaire Administration
Study specific questionnaires

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility of enrollment onto study
Time Frame: At time of randomization
The number of participants enrolled into the study compared to trial goals.
At time of randomization
Proportion of participants who complete baseline and follow-up questionnaires within 60 days of receipt
Time Frame: Up to 3 years
The proportion of participants who are complete questionnaires and timing of completion.
Up to 3 years
Proportion of participants who provide the required blood sample for year 1 for Multi-Cancer Detection (MCD) testing within 90 days of recommended time point
Time Frame: Up to 2 years
The proportion of participants who have a second blood draw and the timing of the blood draw.
Up to 2 years
Proportion of participants considered lost to follow-up within 2 years of randomization
Time Frame: Up to 2 years
The proportion of participants who do not complete study procedures and are not able to be contacted.
Up to 2 years
Representative enrollment
Time Frame: Up to 2 years
Meeting or exceeding the trial enrollment goals on a population basis.
Up to 2 years
Staggered start of intervention arm 2
Time Frame: Up to 1 year
Advantages and challenges arising from trial activation with one intervention arm and later addition of a second intervention arm.
Up to 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Impact of participant blinding
Time Frame: Up to 2 years
Comparisons between blinded and unblinded sites on participation rates, adherence to protocol-required questionnaires and blood collection, and participation in standard of care screening.
Up to 2 years
Timely return of MCD test result
Time Frame: Up to 2 years
The time from receipt of the MCD test result at the Statistics and Data Management Center to the time of receipt of the MCD test result at the ACCESS Hub. The time from receipt of MCD test result at the ACCESS Hub to the time of participant receipt of the MCD test result.
Up to 2 years
Factors contributing to lack of diagnostic resolution of an abnormal MCD test
Time Frame: Up to 2 years
Factors that contribute to the inability to determine if a participant has a cancer or rule out cancer.
Up to 2 years
Contamination
Time Frame: Up to 3 years
Estimated as the number of participants receiving MCD testing outside the trial.
Up to 3 years
Effects of participant characteristics
Time Frame: Up to 2 years
Feasibility outcomes will be reported by participant demographics and cancer risk factors.
Up to 2 years
Diagnostic resolution following an abnormal MCD test result
Time Frame: Within 12 months following an abnormal MCD test result
The proportion of participants with a "cancer diagnosis" or "no cancer diagnosis" among all participants with an abnormal MCD test result
Within 12 months following an abnormal MCD test result
Time to diagnostic resolution
Time Frame: Up to 2 years
The number of days from date of ACCESS Hub receipt of abnormal MCD test result to date of provider-reported diagnostic resolution.
Up to 2 years
Participation in standard of care screening
Time Frame: Up to 2 years
The proportion of participants that receive standard of care cancer screening in each arm.
Up to 2 years
Accuracy of tissue of origin prediction
Time Frame: Up to 2 years
The proportion of diagnosed cancers that match the tissue of origin predicted by an abnormal (positive) MCD test, for each screening episode.
Up to 2 years
Complications related to diagnostic evaluation of an abnormal MCD test result
Time Frame: Up to 1 year
Adverse events occurring in participants undergoing a diagnostic workup following receipt of an abnormal MCD test result.
Up to 1 year
Anxiety and Cancer Worry Questionnaire
Time Frame: Up to 2 years
Participant anxiety will be assessed with the Patient Reported Outcomes Measurement Information System instrument. Cancer-related worry will be assessed using the Lehrman Cancer Worry Scale.
Up to 2 years
Sensitivity of clinical diagnostic performance of each MCD assay
Time Frame: Up to 2 years
Sensitivity will be estimated for each MCD assay. These sensitivities will also be calculated by early- versus late-stage, and for MCD test-targeted cancers and all cancers.
Up to 2 years
Specificity of each MCD assay
Time Frame: 1 year
Specificity will be estimated for each MCD assay.
1 year
Test positive rates
Time Frame: Up to 2 years
The proportion of abnormal MCD tests at each screening episode, and the proportion of participants with at least one abnormal test.
Up to 2 years
False positives
Time Frame: Up to 2 years
The number of participants with an abnormal MCD test and no cancer diagnosis.
Up to 2 years
(Targeted cancer) Positive predictive value (PPV)
Time Frame: Up to 2 years
The proportion of abnormal MCD tests that result in diagnosis of one of the MCD test-targeted cancers among participants with at least one abnormal test, for each screening episode.
Up to 2 years
(All cancer) PPV
Time Frame: Up to 2 years
The proportion of abnormal MCD tests that result in diagnosis of any cancer among participants with at least one abnormal test, for each screening episode.
Up to 2 years
Interval cancers
Time Frame: 1 year
The number of MCD test-targeted cancer cases diagnosed within 12 months of a normal MCD test result among participants who received an MCD test, for each screening episode.
1 year
Detected cancers
Time Frame: 1 year
The number of cancer cases diagnosed within a 12-month follow-up period of an abnormal test result among participants who received an MCD test, for each screening episode.
1 year
(Targeted cancer) Negative predictive value
Time Frame: 1 year
The proportion of normal MCD tests that did not result in diagnosis of one of the MCD test-targeted cancers among participants with a normal test, for each screening episode.
1 year

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cancer stage
Time Frame: Up to 12 years
The stage that a cancer was diagnosed (Surveillance, Epidemiology, and End Results [SEER]).
Up to 12 years
Early and late stages cancer diagnosis
Time Frame: Up to 12 years
Counts of early and late-stage cancers by arm, separately for each cancer type. Early stage is defined as in situ or localized (SEER). Late stage is defined as regional or distant stage (SEER).
Up to 12 years
Targeted cancer-specific mortality of each MCD assay
Time Frame: Up to 12 years
The fraction of MCD-targeted cancers diagnosed during trial participation that resulted in death.
Up to 12 years
Cancer-specific mortality
Time Frame: Up to 12 years
The fraction of all cancers diagnosed during trial participation that resulted in death.
Up to 12 years
All-cause mortality
Time Frame: Up to 12 years
The probability of participant death by any cause during trial participation, by arm.
Up to 12 years
Estimated costs associated with MCD testing minus estimated costs associated with standard of care screening
Time Frame: Up to 12 years
Will estimate average screening costs associated with MCD testing, evaluation of abnormal MCD tests, standard of care screening and evaluation of abnormal standard of care screening results (all MCD arm participants are encouraged to receive standard of care screening), plus cancer site and stage specific treatment costs sourced from the published literature.
Up to 12 years
Participant out of pocket costs
Time Frame: Up to 2 years
Portions of direct medical care costs paid directly by participants (e.g., copays, deductibles and uncovered medical bills) and direct non-medical participant costs; for example, transportation costs, travel time and distance, accommodation costs, childcare or elder-care costs will be elicited through an adapted version of the Costs for Patients Questionnaire.
Up to 2 years
Participant work loss
Time Frame: Up to 2 years
Participant and caregiver time spent away from work will be estimated using an adapted version of the Productivity Cost Questionnaire. The dollar value of hours recorded for participant work loss and caregiver time will be estimated using wages from the Bureau of Labor Statistics.
Up to 2 years
Proportion of participants who complete the Military Exposure Questionnaire
Time Frame: At baseline
Will evaluate the proportion of participants who complete the Military Exposure Questionnaire, among those who reported military service.
At baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Cancer Institute (NCI)

Investigators

  • Principal Investigator: Scott D Ramsey, Fred Hutchinson Cancer Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 18, 2025

Primary Completion (Estimated)

January 31, 2029

Study Completion (Estimated)

June 30, 2029

Study Registration Dates

First Submitted

May 29, 2025

First Submitted That Met QC Criteria

May 29, 2025

First Posted (Actual)

May 30, 2025

Study Record Updates

Last Update Posted (Actual)

June 11, 2026

Last Update Submitted That Met QC Criteria

June 10, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NCI-2024-10793 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
  • P30CA015704 (U.S. NIH Grant/Contract)
  • CSRN1 (Other Identifier: CTEP)
  • UG1CA286954 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Malignant Solid Neoplasm

Clinical Trials on Biospecimen Collection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe